Menu Close

Pfizer recalls all lots of Chantix tablets over excess N-nitroso-varenicline (Full List)

*The drug maker’s product contains more than the acceptable daily intake level of N-nitroso-varenicline

Emmanuel Akosile | ConsumerConnect

For containing more than the acceptable daily intake level of N-nitroso-varenicline, Pfizer is recalling all lots of Chantix 0.5-mg and 1-mg tablets.

ConsumerConnect gathered the anti-smoking product contains N-nitroso-varenicline at or above the US Food and Drug Administration’s interim acceptable intake limit.

Long-term ingestion of N-nitroso-varenicline may be associated with a theoretical potential increased cancer risk, but there is no immediate risk to patients taking this medication.

However, Pfizer has not received any reports of adverse events thus far, agency report stated.

A list of the recalled products may be found HERE.

In regard to what to do in addressing the situation, the company urged consumers who purchased the recalled product to contact Stericycle on (888) 276-6166 Monday – Friday from 8:00 a.m – 5:00 p.m (ET) for instructions on how to return their product and obtain a refund.

Drug maker applies to vaccinate children five to 11

In a related development, Pfizer has filed papers with the FDA, seeking approval to use its COVID-19 Vaccine to inoculate children between the ages of five and 11. Currently, the vaccine is only approved for individuals 12 and older.

If the FDA agrees, young children would receive two injections of the Pfizer-BioNTech vaccine, with the second shot coming three weeks after the first.

Nonetheless, before a decision is made, the clinical trial data will be reviewed by an FDA advisory committee, according to report.

A number of states in the US have reportedly traced the rise in COVID-19 cases to various school districts, whose officials have urged regulators to approve vaccinations for children.

Schools have emerged as a likely venue for vaccinations, much the way they were for the polio vaccine 60 years ago, report noted.

Kindly Share This Story



Kindly share this story